I agree that this site is using cookies. You can find further informations here.
X
Senzer, Neil
110  results:
Search for persons X
?
1

Author Correction: ENTPD1/CD39 as a predictive marker of tr..:

Rocconi, Rodney P. ; Stanbery, Laura ; Tang, Min...
Communications Medicine.  3 (2023)  1 - p. , 2023
Link: https://doi.org/10.1038/..
 
?
2

Corrigendum to "Gemogenovatucel-T (Vigil) immunotherapy dem..:

Rocconi, Rodney P. ; Monk, Bradley J. ; Walter, Adam...
Gynecologic Oncology.  169 (2023)  - p. 173 , 2023
Link: https://doi.org/10.1016/..
 
?
3

ENTPD1/CD39 as a predictive marker of treatment response to..:

Rocconi, Rodney P. ; Stanbery, Laura ; Tang, Min...
Communications Medicine.  2 (2022)  1 - p. , 2022
Link: https://doi.org/10.1038/..
 
?
4

Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinic..:

Rocconi, Rodney P. ; Monk, Bradley J. ; Walter, Adam...
Gynecologic Oncology.  161 (2021)  3 - p. 676-680 , 2021
Link: https://doi.org/10.1016/..
 
?
5

Corrigendum to "Long-term follow-up of Phase 2A trial resul..:

Oh, Jonathan ; Barve, Minal ; Senzer, Neil...
Gynecologic Oncology Reports.  36 (2021)  - p. 100740 , 2021
Link: https://doi.org/10.1016/..
 
?
6

Long-term follow-up of Phase 2A trial results involving adv..:

Oh, Jonathan ; Barve, Minal ; Senzer, Neil...
Gynecologic Oncology Reports.  34 (2020)  - p. 100648 , 2020
Link: https://doi.org/10.1016/..
 
?
7

Bromodomain and Extra-Terminal Motif Inhibitors: a Review o..:

Alqahtani, Ali ; Choucair, Khalil ; Ashraf, Mushtaq...
Future Science OA.  5 (2019)  3 - p. , 2019
Link: https://doi.org/10.4155/..
 
?
8

KRAS mutant allele-specific expression knockdown in pancrea..:

Rao, Donald D. ; Luo, Xiuquan ; Wang, Zhaohui...
PLOS ONE.  13 (2018)  5 - p. e0193644 , 2018
Link: https://doi.org/10.1371/..
 
?
9

Phase II study of Vigil® DNA engineered immunotherapy as ma..:

Oh, Jonathan ; Barve, Minal ; Matthews, Carolyn M....
Gynecologic Oncology.  143 (2016)  3 - p. 504-510 , 2016
Link: https://doi.org/10.1016/..
 
?
10

A Phase II Efficacy and Safety, Open-Label, Multicenter Stu..:

Segal, Neil H. ; Gada, Purvi ; Senzer, Neil...
Clinical Colorectal Cancer.  15 (2016)  3 - p. 222-227 , 2016
Link: https://doi.org/10.1016/..
 
?
11

Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (L..:

Rao, Donald D. ; Jay, Christopher ; Wang, Zhaohui...
Molecular Therapy.  24 (2016)  8 - p. 1412-1422 , 2016
Link: https://doi.org/10.1038/..
 
?
12

Preclinical Biodistribution and Safety Evaluation of a pbi-..:

Wang, Zhaohui ; Jay, Christopher M. ; Evans,, Courtney...
Toxicological Sciences.  155 (2016)  2 - p. 400-408 , 2016
Link: https://doi.org/10.1093/..
 
?
13

Three-year Follow up of GMCSF/bi-shRNAfurin DNA-transfected..:

Ghisoli, Maurizio ; Barve, Minal ; Mennel, Robert...
Molecular Therapy.  24 (2016)  8 - p. 1478-1483 , 2016
Link: https://doi.org/10.1038/..
 
?
14

Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma:

Ghisoli, Maurizio ; Barve, Minal ; Schneider, Reva...
Molecular Therapy.  23 (2015)  6 - p. 1103-1109 , 2015
Link: https://doi.org/10.1038/..
 
?
15

Phase 1 Trial of Bi-shRNA STMN1 BIV in Refractory Cancer:

Barve, Minal ; Wang, Zhaohui ; Kumar, Padmasini...
Molecular Therapy.  23 (2015)  6 - p. 1123-1130 , 2015
Link: https://doi.org/10.1038/..
 
1-15